Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC)
$1.73
-0.0100 ( -0.57% ) 55.1K
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Market Data
Open
$1.73
Previous close
$1.74
Volume
55.1K
Market cap
$2.56M
Day range
$1.72 - $1.78
52 week range
$1.30 - $13.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jun 25, 2024 |
8-k | 8K-related | 17 | May 14, 2024 |
10-q | Quarterly Reports | 61 | May 14, 2024 |
def | Proxies and info statements | 5 | May 08, 2024 |
ars | Annual reports | 1 | May 08, 2024 |
8-k | 8K-related | 24 | May 02, 2024 |
10-k/a | Quarterly Reports | 16 | Apr 29, 2024 |
8-k | 8K-related | 14 | Apr 26, 2024 |
8-k | 8K-related | 14 | Mar 28, 2024 |
10-k | Annual reports | 90 | Mar 21, 2024 |